Close it

Would you like to become a TBEC member? Please fill out the form below.

By becoming a TBEC member, you agree to endorse the values and the principles of the TB Europe Coalition, and agree with its membership rights and responsibilities.

Membership is free of charge.

TBEC membership rights

TBEC membership responsibilities












Posts tagged "Research"

TBEC Capacity Building Workshop

From 16 to 18 September this year, TB Europe Coalition will host a three-day capacity building workshop on TB advocacy and service delivery in London (Vauxhall). The workshop aims to showcase the best practice in TB advocacy and service delivery in the UK, strengthen the organisational capacity of participants via various capacity building activities and enhance peer-to-peer learning and collaboration across the European region. The workshop will gather 9 participants from across the various civil society organisations, working on TB in the wider European region (Bosnia and Herzegovina, Bulgaria, Moldova, Montenegro, the Netherlands, Portugal, Romania, Ukraine). The three-day workshop will focus on: TB advocacy in the UK – engagement with the UK government, members of parliament and international organisations; TB service delivery in the UK – programme governance structures, new TB Strategy, site visits to Find&Treat van and Olollo House; Capacity building – UK best practice in grassroots engagement, health promotion and campaigning; Following the workshop, all participants will use what they have learned for the benefit of their country-based projects. At the moment, the submitted proposals range from developing a research paper to carrying out a broader advocacy campaign to organising a regional civil society network. TBEC members will be able to follow the development of the projects via regular updates on More…

TB vaccine one step closer as a result of effective EU research and development

TB vaccine one step closer as a result of effective EU research and development

European scientists are one step closer to delivering a new, safe and more effective vaccine against tuberculosis developed through EU research funding, according to a press release from the European Commission published yesterday.  The live vaccine, MTBCAC, is the  first to be based on Mycobacterium tuberculosis; a strongly weakened version of the bacterium that causes TB. It should stimulate the human immune system to recognise and eventually prevent TB infection. The TuBerculosis Vaccine Initiative (TBVI), who took part in the pre-clinical development of the vaccine, explain the trial as a big win for scientists all over Europe as the first candidate of its kind ever to be tested in humans. Significantly, the press release symbolises how the vaccine pipeline for TB is better then it ever has been. Along with MTBVAC, MVA85A – the most advanced TB vaccine – is currently in phase 2b trials with results due later this year.  Both of these, whether or not they go any further in the clinical trial stage, undoubtedly serve to advance TB vaccine research even further. If MTBVAC does manage to pass tests and shows good immune responses, it will be able to move to the next phase of evaluation that More…

EU must do more in poverty-related and neglected disease research and development

EU must do more in poverty-related and neglected disease research and development

The critical role played by the EU in research and development (R&D) of poverty-related and neglected diseases has been highlighted in an engaging report and accompanying video, released last week. Significant strides made over the past few decades in the developing world are recognised as a direct result of the EU’s commitment to both world leading research and the development of new drugs. As a result of this commitment, in the past few decades the world has witnessed a 25% reduction in levels of malaria, polio is close to being eradicated and new centres of expertise have emerged all over Latin America, Africa and Asia. Significantly, the video makes note of the fact that in 2010 malaria deaths fell by 335,000. This dramatic decrease can, at least in part, be attributed to the development of Coartem Dispersible, a malaria drug specifically made for children and developed through a  partnership of EU member states and pharmaceutical companies. Continued commitment from the EU and associated parties is vital if we are to see such progress with regards to other PRNDs, such as TB. Successes like that of Coartem Disperisble are critical. However, due to the continuation of the global economic crisis, the More…

Call to EU Leadership on Global Health Research and Development

Call to EU Leadership on Global Health Research and Development

Twenty-three NGOs, including members of the TB Europe Coalition, have come together to call upon the leadership of the EU to support recent WHO recommendations for a clear and effective roadmap towards an international funding commitment for poverty-related and neglected disease (PRND) research and development (R&D). By joining forces with existing national and international initiatives as well as prioritising global health R&D, it is proposed there will be greater coordination that will result in the EU helping to address the highly fragmented landscape that currently exists in health research: “We believe that the EU could become a major player by joining forces with existing national and international initiatives, coordinating and complementing these regional and national efforts in order to ensure that global health products are delivered to patients in a fast and efficient manner.” The EU ultimately has the chance to take a leading position in delivering more effective, fair and efficient treatment with regards to poverty-related and neglected diseases, such as TB. The full document can be downloaded here.

Funding for TB research and development was flat in 2010 compared to 2009

New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005. The report, Tuberculosis Research and Development: 2011 Report on Tuberculosis Research Funding Trends,2005-2010, tracks annual research spending across six TB R&D areas against funding targets set by the Global Plan to Stop TB 2011-2015. The report offers year-to-year data on the leading TB research funders and underscores the urgency of adequate and sustained funding. The 2011 report finds that 71 donors invested $617 million in TB R&D in 2010— less than one-third of the $2 billion annual target the Stop TB Partnership estimates is needed to provide new interventions to eliminate TB. “Recent progress in TB research is clearly threatened by stagnating funding,” said TAG’s executive director, Mark Harrington. “After several years of increasing investment, TB research is finally making headway with two new promising drugs for the treatment of multi-drug resistant TB and a new drug combination active against both drug sensitive and drug resistant TB. More…

New TB roadmap emphasizes critical role of research

“Elimination of tuberculosis (TB) is more than an aspiration. We know it could become a reality, but this will happen only if we achieve radical transformation in the way TB is diagnosed, treated and prevented. This goal can be realized only if TB research is intensified and envisioned in an entirely new way.” These are the first words of Lucica Ditiu, Executive Secretary of Stop TB Partnership, in the International Roadmap of Tuberculosis Research, launched this weekend in Lille. To view the Roadmap click: ROADMAP_web The roadmap includes contributions of TBVI’s director Jelle Thole and is the product of the Research Movement, created by the Stop TB Partnership and the WHO Stop TB Department in 2006 to address the urgent need for increased commitment for TB research. The Research Movement, led by Christian Lienhardt, is intended to provide leadership and advocacy to mobilize increased resources in support of a coherent and comprehensive global TB research agenda to meet the Stop TB goals and targets; and to provide a forum for TB researchers and funders of TB research to coordinate priorities and actions. “Research is a fundamental means to maximize the advances already achieved in TB control through strengthening of programmes and health More…

EU 7th Research Framework Programme call relevant for TB

The FP7 (7th Research Framework Programme of the EU) call has recently been published (20 July). It includes a heading on Detection and Diagnosis as well as a heading on HIV/AIDS, TB and Malaria, both relevant for us and partners. Under 2.3 “Translational research in major infectious diseases: to confront major threats to public health” 2.3.2: HIV/AIDS, TB and Malaria (54 million €) 2.3.2 HEALTH.2012.2.3.2-1: Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis. Collaborative Project (small or medium-scale focused research project). One or more proposals can be selected. Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. 2.3.2 HEALTH.2012.2.3.2-2: Co-morbidity between infectious and noncommunicable diseases. Collaborative Project (small or medium-scale focused research project). One or more proposals can be selected. Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. 2.3.2 HEALTH.2012.2.3.2-3: Prevention and treatment for HIV/AIDS, malaria and tuberculosis. SME-targeted Collaborative Project (small or medium-scale focused research project). One or more proposals can be selected. Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. Projects will only be selected for funding on the condition that the estimated EU contribution going to SMEs is 15% or more of the total More…

wink.pink